Shots:

• Lead Pharma receives ~$11.86M upfront and is eligible to receive funding and ~$307.9 as research- development- regulatory and commercial milestones along with royalties on sales of small molecules
• The companies will collaborate in research activities up to the selection of a pre-clinical candidate after which Roche will be responsible for the development and global commercialization
• The R&D collaboration builds on Lead Pharma's expertise in the discovery- design- and optimization of small-molecule treatments

 ­ Ref: PRNewswire | Image: Roche